Overview

PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Since multiple studies have demonstrated that PET can identify responders and non-responders to induction chemotherapy, using FDG-PET imaging to guide treatment decisions has prompted interest in clinical practice. The aim of this study was to evaluate whether changing chemotherapy regimen during radiation based on PET response to induction chemotherapy can improve clinical complete response (cCR) in patients with unresectable esophageal squamous cell carcinoma (ESCC).
Phase:
Phase 2
Details
Lead Sponsor:
Mian XI
Treatments:
Cisplatin
Fluorouracil
Leucovorin
Oxaliplatin
Paclitaxel